Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Laryngeal cancer statistics
New cases of head and neck cancer, 2015, UK
Deaths from laryngeal cancer, 2014, UK
Survive head and neck cancers for 10 or more years, 2009-13, England
- There are around 11,700 new head and neck cancer cases in the UK every year, that's 32 every day (2013-2015).
- Head and neck cancer is the 8th most common cancer in the UK, accounting for 3% of all new cancer cases (2015).
- In males in the UK, head and neck cancer is the 4th most common cancer, with around 8,400 new cases in 2015.
- In females in the UK, head and neck cancer is the 13th most common cancer, with around 3,700 new cases in 2015.
- Incidence rates for head and neck cancer in the UK are highest in people aged 70 to 74 (2013-2015).
- Since the early 1990s, head and neck cancer incidence rates have increased by almost a third (31%) in the UK. Rates in males have increased by more than a fifth (22%), and rates in females have increased by two-fifths (40%).
- Over the last decade, head and neck cancer incidence rates have increased by around a quarter (24%) in the UK. Rates in males have increased by a fifth (20%), and rates in females have increased by around a quarter (26%).
- More than 6 in 10 head and neck cancer cases are diagnosed at a late stage in Northern Ireland (2010-2014).
- Most head and neck cancers occur in the larynx.
- Incidence rates for laryngeal cancer are projected to fall by 17% in the UK between 2014 and 2035, to 4 cases per 100,000 people by 2035.
- 1 in 175 men and 1 in 800 women will be diagnosed with laryngeal cancer during their lifetime.
- 1 in 75 men and 1 in 150 women will be diagnosed with oral cancer during their lifetime.
- Head and neck cancer in England is more common in people living in the most deprived areas.
- Worldwide, it is estimated that there were more than 425,000 men and women still alive in 2008, up to five years after being diagnosed with laryngeal cancer.
- In Europe, around 39,900 new cases of laryngeal cancer were estimated to have been diagnosed in 2012. The UK incidence rate is seventh lowest in Europe for males and 15th highest for females.
- Worldwide around 157,000 new cases of laryngeal cancer were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- There were around 840 laryngeal cancer deaths in the UK in 2014, that’s more than 2 deaths every day.
- Laryngeal cancer accounts for less than 1% of all cancer deaths in the UK (2014).
- In males in the UK, laryngeal cancer is the 17th most common cause of cancer death, with around 680 deaths in 2014.
- In females in the UK, there were around 160 laryngeal cancer deaths in 2014.
- Almost 6 in 10 (58%) laryngeal cancer deaths in the UK each year are in people aged 70 and over (2012-2014).
- Mortality rates for laryngeal cancer in the UK are highest in people aged 85+ (2012-2014).
- Since the early 1970s, laryngeal cancer mortality rates have decreased by almost a third (30%) in the UK. The decrease is larger in males (40%), than in females (21%).
- Over the last decade, laryngeal cancer mortality rates have decreased by a tenth (10%) in males and females combined in the UK, however this includes a decrease (11%) in males and stable rates in females.
- Mortality rates for laryngeal cancer are projected to fall by less than 1% in the UK between 2014 and 2035, to 2 deaths per 100,000 people by 2035.
- Overall, head and neck cancer deaths in England are more common in people living in the most deprived areas.
- In Europe, around 19,800 people were estimated to have died from laryngeal cancer in 2012. The UK mortality rate is sixth lowest in Europe for males and 20th highest for females.
- Worldwide, around 83,400 people were estimated to have died from laryngeal cancer in 2012, with mortality rates varying across the world.
- Between 19% and 59% of people diagnosed with head and neck cancers in England survive their disease for ten years or more (2009-13).
- Between 28% and 67% of people diagnosed with head and neck cancers in England survive their disease for five years or more (2009-13).
- Between 61% and 86% of people diagnosed with head and neck cancers in England survive their disease for one year or more (2009-13).
- Survival varies by head and neck cancer subtype in England and is highest in salivary glands cancer and lowest in hypopharyngeal cancer (one-, five- and ten-year survival, 2009-2013).
- Head and neck cancers 10-year survival in England is generally similar in men and women (2009-13), though the size of the sex difference varies by subtype.
- Head and neck cancers survival in England is generally higher for people diagnosed aged 15-49 compared with other age groups, though the association with age varies by subtype.
- Salivary glands cancer survival has the widest gap between age groups among head and neck cancer subtypes: 9 in 10 people in England diagnosed with salivary glands cancer aged 15-49 survive their disease for five years or more, compared with 5 in 10 people diagnosed aged 70-89 (2009-2013).
- Laryngeal cancer survival is improving and has increased in the last 40 years in the UK.
- In the 1970s, around half of men diagnosed with laryngeal cancer survived their disease beyond ten years, now it's more than 6 in 10.
- When diagnosed at its earliest stage, around 9 in 10 of men with laryngeal cancer will survive their disease for five years or more, compared with more than 4 in 10 of people when diagnosed at the latest stage.
- Five-year relative survival for most head and neck cancer types in males is similar to or above the European average in England, Wales, Scotland and Northern Ireland.
- Five-year relative survival for most head and neck cancer types in females is similar to or above the European average in England, Wales, Scotland and Northern Ireland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 91% (93% in males and 85% in females) of oral cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- 93% of laryngeal cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- Risk factors vary by the specific site of head and neck cancer.
- Smoking is the main avoidable risk factor for head and neck cancer, linked to an estimated 65% of oral cancer cases, and an estimated 79% of laryngeal cancer cases in the UK.
- An estimated 91% of oral cancers in the UK are linked to lifestyle factors including smoking, alcohol (30%), and infections (13%).
- An estimated 93% of laryngeal cancers in the UK are linked to lifestyle factors including smoking, and alcohol (25%).
- Betel quid, smokeless tobacco, ionising radiation and certain occupational exposures cause oral cancer.
- Certain occupational exposures cause laryngeal cancer.
- A diet high in fruit and vegetables may protect against head and neck cancer – insufficient fruit and vegetables intake is linked to an estimated 56% of oral cancer cases, and an estimated 45% of laryngeal cancer cases in the UK.
- Environmental tobacco smoke and solar radiation may relate to higher risk of some oral cancer types, but evidence is unclear.
- HPV infection, environmental tobacco smoke, and certain medical conditions may relate to higher laryngeal cancer risk, but evidence is unclear.
- 'Two-week wait' standards are met by all countries, '31-day wait' is met by all but Wales, and ‘62-day wait’ is not met by any country for head and neck cancers.
- Treatment for head and neck cancer varies for each cancer type.
- Between 32% to 75% of patients diagnosed with head and neck cancers cancer have surgery to remove the tumour as part of their primary cancer treatment.
- Between 43% and 85% of patients diagnosed with head and neck cancers have radiotherapy as part of their primary cancer treatment.
- Between 8% and 61% of patients diagnosed with head and neck cancers have chemotherapy as part of their primary cancer treatment.
The latest statistics available for laryngeal cancer in the UK are; incidence 2015, mortality 2014 and survival 2009-2013.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Due to the small numbers of women diagnosed with laryngeal cancer each year, most of the survival data refers to males only.
Survival by stage is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past. Survival by stage is available for the former Anglia Cancer Network in the east of England, however. The former Anglia Cancer Network covers around 5% of the population of England and may not be representative of the country as a whole due to differences in underlying demographic factors (such as age, deprivation or ethnicity), as well as variation in local healthcare provision standards and policies.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Laryngeal cancer is part of the group 'Head and Neck cancers' for cancer waiting times data. Codes vary per country but broadly include: lip, tongue, gum, floor of mouth, palate, other and unspecified parts of mouth, parotid gland, salivary glands, tonsil, oropharynx, nasopharynx, piriform sinus, hypopharynx, other ill-defined site of lip, oral cavity and pharynx, nasal cavity and middle ear, accessory sinuses, larynx, thyroid and lymph nodes and other and ill-defined sites of the head, face and neck.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.